A vs KNSA: fair value comparison
Agilent Technologies, Inc. and Kiniksa Pharmaceuticals International, plc · Updated 2026-09-06
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, KNSA currently sits closer to the top of our discount ranking. A carries the stronger quality grade.
| A | KNSA | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $150.86 | $73.41 |
| 12-month range | $114.52–$150.10 | $37.47–$73.41 |
| Sector rank | #59 of 113 Healthcare | #58 of 113 Healthcare |
| Quality grade | C | D |
| Leverage | Moderate | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: A fair value analysis · KNSA fair value analysis